Alphatec's (ATEC) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Alphatec Holdings (NASDAQ: ATEC) has had its "sell (D-)" rating reaffirmed by Weiss Ratings as of Tuesday, indicating potential challenges ahead for the company.
• In a contrasting view, Barclays has given Alphatec an "overweight" rating with a price target increase to $22.00, reflecting some analyst confidence in the stock's potential.
• The company reported a 27.5% increase in revenue year-over-year in its latest earnings report, surpassing analyst expectations with earnings per share of $0.02.

Alphatec (NASDAQ:ATEC - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Other equities analysts also recently issued research reports about the company. Barclays reissued an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a report on Monday, June 16th. Wall Street Zen lowered shares of Alphatec from a "buy" rating to a "hold" rating in a research report on Friday, September 26th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $20.00 target price on shares of Alphatec in a research report on Friday, August 1st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Alphatec has a consensus rating of "Moderate Buy" and a consensus price target of $18.50.

Alphatec Price Performance

ATEC stock traded up $0.36 during midday trading on Tuesday, hitting $13.60. 608,739 shares of the stock were exchanged, compared to its average volume of 2,030,889. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -12.03 and a beta of 1.05. Alphatec has a fifty-two week low of $5.08 and a fifty-two week high of $16.70. The stock's 50-day moving average price is $15.23 and its 200-day moving average price is $12.70. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. During the same quarter in the previous year, the firm posted ($0.29) EPS. The business's revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Research analysts predict that Alphatec will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Alphatec

In other news, Director Mortimer Berkowitz III sold 62,500 shares of Alphatec stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $15.97, for a total value of $998,125.00. Following the transaction, the director directly owned 618,050 shares of the company's stock, valued at $9,870,258.50. The trade was a 9.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP David Sponsel sold 2,555 shares of the stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $15.34, for a total transaction of $39,193.70. Following the sale, the executive vice president directly owned 531,861 shares of the company's stock, valued at approximately $8,158,747.74. This trade represents a 0.48% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 780,575 shares of company stock worth $11,769,527. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Large investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Alphatec by 301.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock valued at $608,000 after acquiring an additional 45,027 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after buying an additional 2,306 shares during the period. SG Americas Securities LLC grew its stake in shares of Alphatec by 28.3% in the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock valued at $577,000 after buying an additional 12,553 shares in the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after buying an additional 1,552 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in Alphatec by 6.9% during the 1st quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock worth $1,508,000 after acquiring an additional 9,661 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.